<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Thought du Jour &#187; pharma</title>
	<atom:link href="http://larrywillmore.net/blog/index.php/tag/pharma/feed/" rel="self" type="application/rss+xml" />
	<link>http://larrywillmore.net/blog</link>
	<description>Semi-daily posts, related largely to economics and government policy</description>
	<lastBuildDate>Wed, 08 Feb 2012 14:34:51 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.5</generator>
		<item>
		<title>subsidies for big pharma</title>
		<link>http://larrywillmore.net/blog/2010/10/02/subsidies-for-big-pharma/</link>
		<comments>http://larrywillmore.net/blog/2010/10/02/subsidies-for-big-pharma/#comments</comments>
		<pubDate>Sat, 02 Oct 2010 12:29:54 +0000</pubDate>
		<dc:creator>Larry Willmore</dc:creator>
				<category><![CDATA[Health Economics]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://larrywillmore.net/blog/?p=1559</guid>
		<description><![CDATA[George W. Bush&#8217;s $600 billion subsidy of prescription drugs for seniors (Medicare Modernization Act of 2003) was a bonanza for pharmaceutical companies, but did it reduce expenditure on other health care services or improve the lives of seniors? Apparently not, concludes a study of the records of 12,000 nationally representative seniors who were interviewed four [...]]]></description>
		<wfw:commentRss>http://larrywillmore.net/blog/2010/10/02/subsidies-for-big-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>kidney transplants and dialysis</title>
		<link>http://larrywillmore.net/blog/2009/12/15/kidney-transplants-and-dialysis/</link>
		<comments>http://larrywillmore.net/blog/2009/12/15/kidney-transplants-and-dialysis/#comments</comments>
		<pubDate>Tue, 15 Dec 2009 10:08:09 +0000</pubDate>
		<dc:creator>Larry Willmore</dc:creator>
				<category><![CDATA[Health Economics]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[rationing]]></category>

		<guid isPermaLink="false">http://larrywillmore.net/blog/?p=592</guid>
		<description><![CDATA[Outrageous news from the USA. Although Medicare is primarily an insurance program for older Americans and the disabled, it has since 1973 covered those with end-stage renal disease, regardless of their age or condition. The federal program now pays for most costs associated with dialysis and transplantation. But for patients younger than 65, coverage of [...]]]></description>
		<wfw:commentRss>http://larrywillmore.net/blog/2009/12/15/kidney-transplants-and-dialysis/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>how big pharma prevents competition</title>
		<link>http://larrywillmore.net/blog/2009/12/09/how-big-pharma-prevents-competition/</link>
		<comments>http://larrywillmore.net/blog/2009/12/09/how-big-pharma-prevents-competition/#comments</comments>
		<pubDate>Wed, 09 Dec 2009 09:46:54 +0000</pubDate>
		<dc:creator>Larry Willmore</dc:creator>
				<category><![CDATA[Health Economics]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://larrywillmore.net/blog/?p=565</guid>
		<description><![CDATA[The Wall Street Journal&#8216;s Health Blog has an article explaining how Abbott is able to prevent generic competition in its sales of TriCor, a cholesterol-reducing drug first marketed in Europe in 1975. The reason: Abbott licensed the compound to sell in the U.S. in 1998, and has been jockeying to keep it patented ever since [...]]]></description>
		<wfw:commentRss>http://larrywillmore.net/blog/2009/12/09/how-big-pharma-prevents-competition/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>marketing prescription drugs</title>
		<link>http://larrywillmore.net/blog/2009/12/03/marketing-prescription-drugs/</link>
		<comments>http://larrywillmore.net/blog/2009/12/03/marketing-prescription-drugs/#comments</comments>
		<pubDate>Thu, 03 Dec 2009 09:52:06 +0000</pubDate>
		<dc:creator>Larry Willmore</dc:creator>
				<category><![CDATA[Health Economics]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://larrywillmore.net/blog/?p=531</guid>
		<description><![CDATA[The US Congressional Budget Office (CBO) yeseterday released an 8-page report on how pharmaceutical companies promote prescription drugs. The way that pharmaceutical manufacturers promote prescription drugs has changed significantly in the past decade. Until the late 1990s, pharmaceutical manufacturers confined their marketing efforts largely to physicians and other health care providers. In the late 1990s, [...]]]></description>
		<wfw:commentRss>http://larrywillmore.net/blog/2009/12/03/marketing-prescription-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>placebos are becoming more effective</title>
		<link>http://larrywillmore.net/blog/2009/08/26/placebos-are-becoming-more-effective/</link>
		<comments>http://larrywillmore.net/blog/2009/08/26/placebos-are-becoming-more-effective/#comments</comments>
		<pubDate>Wed, 26 Aug 2009 21:05:37 +0000</pubDate>
		<dc:creator>Larry Willmore</dc:creator>
				<category><![CDATA[Health Economics]]></category>
		<category><![CDATA[pharma]]></category>

		<guid isPermaLink="false">http://larrywillmore.net/blog/?p=73</guid>
		<description><![CDATA[From 2001 to 2006, the percentage of new [pharmaceutical] products cut from development after Phase II clinical trials, when drugs are first tested against placebo, rose by 20 percent. The failure rate in more extensive Phase III trials increased by 11 percent, mainly due to surprisingly poor showings against placebo. &#8230;. It&#8217;s not only trials [...]]]></description>
		<wfw:commentRss>http://larrywillmore.net/blog/2009/08/26/placebos-are-becoming-more-effective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.384 seconds -->

